Centre for AMR Microbiome Research & Innovations

Centre for AMR Microbiome Research & Innovations (CAMBRI)

The global threat of antimicrobial resistance (AMR) is a leading cause of death worldwide, carrying severe economic and clinical burdens. CAMBRI is established ithin the Yong Loo Lin School of Medicine to consolidate translational research efforts and address the dynamic interplay between AMR and the microbiome.

Main Mission

CAMBRI’s mission is to bridge the gap in the local and regional research ecosystem by unifying and sharpening the translational focus on AMR and microbiome research. By exploring synergies across National University of Singapore (NUS) and National University Health Systems (NUHS), the Centre aims to transform clinical practice, influence public health policy, and develop innovative solutions to combat the evolution, transmission, and burden of drug-resistant pathogens.

Key Aims & Objectives

Address the AMR-Microbiome Interplay: Focus specifically on clinical settings, community carriage, and transmission, while mining microbiomes for anti-resistance strategies and preserving microbiome health.
Drive Translational Solutions: Accelerate the pipeline for novel therapeutics, diagnostics, vaccines, and stewardship strategies targeting critical Gram-negative bacteria (such as CRE and CRAB).
Nucleate ‘One Health’ Research: Expand research capabilities to address the broader interplay of resistance elements across environmental and human reservoirs.
Establish Global & Regional Leadership: Position NUS/NUHS as a primary hub for AMR research in South and Southeast Asia.

Core Capabilities & Strategic Advantages

CAMBRI leverages a unique partnership between the Yong Loo Lin School of Medicine’s Infectious Diseases Translational Research Programme (IDTRP) and ADVANCE-ID at the Saw Swee Hock School of Public Health. Its capabilities are anchored by world-class infrastructure and top-tier expertise:

Clinical Trial & Network Capabilities
- ADVANCE-ID Clinical Network: Access to the largest infectious diseases clinical research network led out of Singapore, encompassing over 100 active sites across Asia. This network enables rapid collection of clinical data, patient samples, and pathogens, as well as the execution of large-scale clinical trials.
- Global Influence: Direct connection to the WHO Global Clinical Trials Forum, shaping international therapeutic guidelines and clinical trial practices.
Advanced Research Infrastructure & Strengths
- Microbiome & Surveillance Excellence: Capabilities in metagenomic surveillance (including Singapore’s land, sea, and air checkpoints), microbiome modeling, and the use of cutting-edge mini-bioreactor array technology alongside germ-free mouse models for pre-clinical validation.
- Diverse Therapeutic Pipelines: Active research pipelines spanning phage biology/therapy, broad-spectrum antibody therapeutics, monoclonal antibodies, and bacterial capsule/vaccine development.